Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TRPC3 | Q13507 | 2/20 | 0.43 |
| ▸ | TRPC7 | Q9HCX4 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2330385 | 0.81 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9APDE4BCYP2C19 | |
| SCHEMBL12660048 | 0.76 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9APDE4BCYP2C19 | |
| SCHEMBL11075243 | 0.76 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9APDE4BCYP2C19 | |
| SCHEMBL309611 | 0.76 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1RAB9APDE4BCYP2C19 | |
| SCHEMBL971318 | 0.76 | SMN1; SMN2 (0.70) | SMN1; SMN2NPC1RAB9APDE4BCYP2C19 | |
| SCHEMBL15865383 | 0.76 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9APDE4BCYP2C19 | |
| SCHEMBL8419487 | 0.75 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9APDE4BCYP2C19 | |
| SCHEMBL21585578 | 0.75 | SMN1; SMN2 (0.45) | SMN1; SMN2NPC1RAB9APDE4BCYP2C19 | |
| SCHEMBL13716189 | 0.74 | SMN1; SMN2 (0.72) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL29132046 | 0.74 | SMN1; SMN2 (0.72) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513424-B2 | Pyridone GPR119 G protein-coupled receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-20 | — | — | US | disclosed |
| US-20120258959-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2012-10-11 | — | — | US | disclosed |
| US-8232404-B2 | Pyridone GPR119 G protein-coupled receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-07-31 | — | — | US | disclosed |
| US-20110245227-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-06 | — | — | US | disclosed |
| EP-2170864-B1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2011-09-14 | — | — | EP | disclosed |
| US-8003796-B2 | Pyridone GPR119 G protein-coupled receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-23 | — | — | US | disclosed |
| EP-2170864-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | Bristol-Myers Squibb Company (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20090023702-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-22 | — | — | US | disclosed |
| WO-2009012275-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258959-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | GPR119, GPR65, GPR27 | SMN1; SMN2 2669/4885NPC1 2115/4885RAB9A 890/4885 |
| US-20110245227-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | GPR119, GPR65, GPR27 | SMN1; SMN2 2669/4885NPC1 2115/4885RAB9A 890/4885 |
| US-20090023702-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | GPR119, GPR65, GPR27 | SMN1; SMN2 2776/4885NPC1 1988/4885RAB9A 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.